BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Moreno S, Perno CF, Mallon PW, Behrens G, Corbeau P, Routy JP, Darcis G. Two-drug vs. three-drug combinations for HIV-1: Do we have enough data to make the switch? HIV Med 2019;20 Suppl 4:2-12. [PMID: 30821898 DOI: 10.1111/hiv.12716] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Gabuzda D, McArthur JC, Letendre SL. Efficacy and safety of two-drug regimens for treatment of HIV in the central nervous system. AIDS 2020;34:1975-7. [PMID: 33009012 DOI: 10.1097/QAD.0000000000002665] [Reference Citation Analysis]
2 Krentz HB, Campbell S, Lahl M, Gill MJ. Uptake Success and Cost Savings from Switching to a Two-Drug Antiretroviral Regimen. AIDS Patient Care STDS 2021. [PMID: 34910887 DOI: 10.1089/apc.2021.0118] [Reference Citation Analysis]
3 van Welzen BJ, Oomen PGA, Hoepelman AIM. Dual Antiretroviral Therapy-All Quiet Beneath the Surface? Front Immunol 2021;12:637910. [PMID: 33643320 DOI: 10.3389/fimmu.2021.637910] [Reference Citation Analysis]
4 Hobson JJ, Curley P, Savage AC, Al-khouja A, Siccardi M, Flexner C, Meyers CF, Owen A, Rannard SP. Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulations. Nanoscale Adv 2019;1:4301-7. [DOI: 10.1039/c9na00529c] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
5 Löscher W, Klein P. New approaches for developing multi-targeted drug combinations for disease modification of complex brain disorders. Does epilepsy prevention become a realistic goal? Pharmacol Ther 2021;:107934. [PMID: 34216705 DOI: 10.1016/j.pharmthera.2021.107934] [Reference Citation Analysis]
6 Menne S, Wildum S, Steiner G, Suresh M, Korolowicz K, Balarezo M, Yon C, Murreddu M, Hong X, Kallakury BV, Tucker R, Yang S, Young JAT, Javanbakht H. Efficacy of an Inhibitor of Hepatitis B Virus Expression in Combination With Entecavir and Interferon-α in Woodchucks Chronically Infected With Woodchuck Hepatitis Virus. Hepatol Commun 2020;4:916-31. [PMID: 32490326 DOI: 10.1002/hep4.1502] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
7 Papot E, Kaplan R, Vitoria M, Polizzotto MN. Optimizing switching strategies to simplify antiretroviral therapy: the future of second-line from a public health perspective. AIDS 2021;35:S153-63. [PMID: 34848582 DOI: 10.1097/QAD.0000000000003108] [Reference Citation Analysis]
8 Sok P, Mgbere O, Pompeii L, Essien EJ. Evaluation of the Sociodemographic, Behavioral and Clinical Influences on Complete Antiretroviral Therapy Adherence Among HIV-Infected Adults Receiving Medical Care in Houston, Texas. HIV AIDS (Auckl) 2021;13:539-55. [PMID: 34040451 DOI: 10.2147/HIV.S303791] [Reference Citation Analysis]
9 Surve DH, Jindal AB. Recent advances in long-acting nanoformulations for delivery of antiretroviral drugs. J Control Release 2020;324:379-404. [PMID: 32461114 DOI: 10.1016/j.jconrel.2020.05.022] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
10 Krovi SA, Johnson LM, Luecke E, Achilles SL, van der Straten A. Advances in long-acting injectables, implants, and vaginal rings for contraception and HIV prevention. Adv Drug Deliv Rev 2021;176:113849. [PMID: 34186143 DOI: 10.1016/j.addr.2021.113849] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Lee YL, Lin KY, Cheng SH, Lu PL, Wang NC, Ho MW, Yang CJ, Liou BH, Tang HJ, Huang SS, Huang SH, Chen TC, Lin CY, Lin SP, Lee YT, Hung CC; Taiwan HIV Study Group. Dual therapy with dolutegravir plus boosted protease inhibitor as maintenance or salvage therapy in highly experienced people living with HIV. Int J Antimicrob Agents 2021;58:106403. [PMID: 34289404 DOI: 10.1016/j.ijantimicag.2021.106403] [Reference Citation Analysis]
12 Abdella S, Youssef SH, Afinjuomo F, Song Y, Fouladian P, Upton R, Garg S. 3D Printing of Thermo-Sensitive Drugs. Pharmaceutics 2021;13:1524. [PMID: 34575600 DOI: 10.3390/pharmaceutics13091524] [Reference Citation Analysis]
13 de Castro Barbosa E, Alves TMA, Kohlhoff M, Jangola STG, Pires DEV, Figueiredo ACC, Alves ÉAR, Calzavara-Silva CE, Sobral M, Kroon EG, Rosa LH, Zani CL, de Oliveira JG. Searching for plant-derived antivirals against dengue virus and Zika virus. Virol J 2022;19:31. [PMID: 35193667 DOI: 10.1186/s12985-022-01751-z] [Reference Citation Analysis]
14 Darcis G, Berkhout B, Pasternak AO. Differences in HIV Markers between Infected Individuals Treated with Different ART Regimens: Implications for the Persistence of Viral Reservoirs. Viruses 2020;12:E489. [PMID: 32349381 DOI: 10.3390/v12050489] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Pierone G, Henegar C, Fusco J, Vannappagari V, Aboud M, Ragone L, Fusco G. Two-drug antiretroviral regimens: an assessment of virologic response and durability among treatment-experienced persons living with HIV in the OPERA® Observational Database. J Int AIDS Soc 2019;22:e25418. [PMID: 31802641 DOI: 10.1002/jia2.25418] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
16 Trunfio M, Rugge W, Mighetto L, Vai D, Atzori C, Nigra M, Domini S, Borgogno E, Guastamacchia G, Bonora S, Di Perri G, Calcagno A. Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV. AIDS 2020;34:1899-906. [PMID: 32701580 DOI: 10.1097/QAD.0000000000002601] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Stellbrink HJ, Lazzarin A, Woolley I, Llibre JM. The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV. HIV Med 2020;21 Suppl 1:3-16. [PMID: 32017355 DOI: 10.1111/hiv.12833] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
18 Jayatunga DPW, Hone E, Fernando WMADB, Garg ML, Verdile G, Martins RN. A Synergistic Combination of DHA, Luteolin, and Urolithin A Against Alzheimer’s Disease. Front Aging Neurosci 2022;14:780602. [DOI: 10.3389/fnagi.2022.780602] [Reference Citation Analysis]
19 Ward D, Ramgopal M, Riedel DJ, Garris C, Dhir S, Waller J, Roberts J, Mycock K, Oglesby A, Collins B, Dominguez M, Pike J, Mrus J. Real-World Experience with Dolutegravir-Based Two-Drug Regimens. AIDS Res Treat 2020;2020:5923256. [PMID: 32724674 DOI: 10.1155/2020/5923256] [Reference Citation Analysis]
20 Yusuf H, Agwu A. Adolescents and young adults with early acquired HIV infection in the united states: unique challenges in treatment and secondary prevention. Expert Rev Anti Infect Ther 2021;19:457-71. [PMID: 32990092 DOI: 10.1080/14787210.2021.1829473] [Reference Citation Analysis]
21 Pérez-gonzález A, Suárez-garcía I, Ocampo A, Poveda E. Two-Drug Regimens for HIV—Current Evidence, Research Gaps and Future Challenges. Microorganisms 2022;10:433. [DOI: 10.3390/microorganisms10020433] [Reference Citation Analysis]
22 Younas M, Psomas C, Reynes C, Cezar R, Kundura L, Portalès P, Merle C, Atoui N, Fernandez C, Le Moing V, Barbuat C, Sotto A, Sabatier R, Winter A, Fabbro P, Vincent T, Reynes J, Corbeau P. Residual Viremia Is Linked to a Specific Immune Activation Profile in HIV-1-Infected Adults Under Efficient Antiretroviral Therapy. Front Immunol 2021;12:663843. [PMID: 33859653 DOI: 10.3389/fimmu.2021.663843] [Cited by in F6Publishing: 1] [Reference Citation Analysis]